Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, will give a presentation of the NeoLIPA trial with LTX-315 at the the 15th Nordic Melanoma Meeting in Reykjavik on 11-13 October 2023.
The title of the presentation is: Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma (NeoLIPA trial): Protocol for a single center phase II open label study.
NeoLIPA is a Phase II open label clinical trial of neoadjuvant LTX-315 in combination with Keytruda® (pembrolizumab), in 27 patients with clinically detectable and resectable stage III-IV melanoma.
Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. Neoadjuvant checkpoint inhibition has been shown to significantly reduce the risk of relapse for high-risk melanoma compared to adjuvant therapy, however many patients still have little effect of the treatment. Consequently, there is a need for novel, more efficient neoadjuvant treatment regimens, and in the NeoLIPA study LTX-315 will be added to standard of care combined with pembrolizumab.
The presentation will hypothesize that intratumoral administration of the LTX-315 will enhance the effect of pembrolizumab as a neoadjuvant treatment prior to surgery for stage III or IV melanoma.
Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented: “Lytix’s unique technology may offer a novel solution to one of the major challenges in today’s cancer treatment. This neoadjuvant study presents an opportunity to demonstrate whether LTX-315 in combination with standard-of-care treatment in neoadjuvant setting could enhance the clinical outcome in early-stage melanoma patients.
Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, added: “With its proposed dual mode of action, LTX-315 is a promising drug for combination with a PD-1 inhibitor in the neoadjuvant setting. By directly killing cancer cells in the injected lesion, LTX-315 can shrink the tumor locally before surgery, and at the same time induce tumor-specific immune responses in the patient before surgery that potentially can reduce the risk of relapse of the disease after surgery.